Top-Rated StocksTop-RatedNASDAQ:BMEA Biomea Fusion (BMEA) Stock Price, News & Analysis $1.81 -0.10 (-5.24%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.82 +0.01 (+0.83%) As of 06/20/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biomea Fusion Stock (NASDAQ:BMEA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biomea Fusion alerts:Sign Up Key Stats Today's Range$1.79▼$1.9550-Day Range$1.39▼$2.9052-Week Range$1.29▼$13.07Volume2.50 million shsAverage Volume1.13 million shsMarket Capitalization$68.00 millionP/E RatioN/ADividend YieldN/APrice Target$21.40Consensus RatingBuy Company OverviewBiomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Read More… Biomea Fusion Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreBMEA MarketRank™: Biomea Fusion scored higher than 49% of companies evaluated by MarketBeat, and ranked 513th out of 926 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingBiomea Fusion has received a consensus rating of Buy. The company's average rating score is 3.18, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBiomea Fusion has only been the subject of 4 research reports in the past 90 days.Read more about Biomea Fusion's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biomea Fusion are expected to grow in the coming year, from ($3.93) to ($3.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomea Fusion is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomea Fusion is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomea Fusion has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Biomea Fusion's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted31.59% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Biomea Fusion has recently increased by 0.88%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomea Fusion does not currently pay a dividend.Dividend GrowthBiomea Fusion does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted31.59% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Biomea Fusion has recently increased by 0.88%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News Sentiment0.64 News SentimentBiomea Fusion has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Biomea Fusion this week, compared to 3 articles on an average week.Search Interest28 people have searched for BMEA on MarketBeat in the last 30 days. This is an increase of 460% compared to the previous 30 days.MarketBeat FollowsOnly 15 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biomea Fusion insiders have not sold or bought any company stock.Percentage Held by Insiders18.42% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.72% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biomea Fusion's insider trading history. Receive BMEA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter. Email Address BMEA Stock News HeadlinesBiomea Fusion Closes $37.1M Stock OfferingJune 20 at 5:31 PM | tipranks.comBiomea Fusion stock falls after announcing public offeringJune 18, 2025 | au.investing.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.June 22, 2025 | Porter & Company (Ad)Biomea Fusion Shares Fall After Pricing Underwritten Public OfferingJune 18, 2025 | marketwatch.comBiomea Fusion Announces Pricing of Public Offering of SecuritiesJune 17, 2025 | globenewswire.comBiomea Fusion, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and WarrantsJune 17, 2025 | quiverquant.comBiomea Fusion Announces Proposed Public Offering of SecuritiesJune 17, 2025 | globenewswire.comBiomea Fusion Reports Preliminary Phase I Clinical Data for BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025 CongressJune 14, 2025 | nasdaq.comSee More Headlines BMEA Stock Analysis - Frequently Asked Questions How have BMEA shares performed this year? Biomea Fusion's stock was trading at $3.88 at the start of the year. Since then, BMEA shares have decreased by 53.4% and is now trading at $1.81. View the best growth stocks for 2025 here. How were Biomea Fusion's earnings last quarter? Biomea Fusion, Inc. (NASDAQ:BMEA) posted its quarterly earnings data on Monday, May, 5th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.84) by $0.04. When did Biomea Fusion IPO? Biomea Fusion (BMEA) raised $120 million in an initial public offering on Friday, April 16th 2021. The company issued 7,500,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO. Who are Biomea Fusion's major shareholders? Biomea Fusion's top institutional investors include Federated Hermes Inc. (1.58%), Nuveen LLC (0.72%), AQR Capital Management LLC (0.70%) and Charles Schwab Investment Management Inc. (0.48%). Insiders that own company stock include Bihua Chen, A2a Pharmaceuticals, Inc and Michael JM Hitchcock. View institutional ownership trends. How do I buy shares of Biomea Fusion? Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biomea Fusion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biomea Fusion investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings5/05/2025Today6/21/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BMEA CIK1840439 Webwww.biomeafusion.com Phone650-980-9099FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$21.40 High Stock Price Target$54.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,082.3%Consensus RatingBuy Rating Score (0-4)3.18 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($3.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$138.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-197.71% Return on Assets-134.84% Debt Debt-to-Equity RatioN/A Current Ratio2.25 Quick Ratio2.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book1.27Miscellaneous Outstanding Shares37,570,000Free Float30,651,000Market Cap$68.00 million OptionableOptionable Beta-0.23 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:BMEA) was last updated on 6/22/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Biggest Story of My Decade-Long Career in Silicon ValleySteve Jobs' Lost 'Product' Could Save Tesla On July 21st, a revolutionary announcement could transform Tesl...InvestorPlace | Sponsored379 passengers walked away from thisForget OpenAI, ChatGPT, and the $2 trillion chip race… The real story is buried inside a new U.S. patent. E...True Market Insiders | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredTrump Makes Major Crypto AnnouncementTrump's crypto revolution is now fully underway and now, we believe he’s about to deliver on his biggest promi...Crypto 101 Media | SponsoredWar Tensions Are Making Gold Rise to Record HighsIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.